The post MetaMask rolls out Transaction Shield, a new transaction loss protection feature appeared on BitcoinEthereumNews.com. Key Takeaways MetaMask introduces Transaction Shield, a premium opt in security upgrade with transaction loss protection and priority support. Subscribers receive coverage up to $10,000 per month for transactions deemed safe by MetaMask’s security systems. MetaMask introduced Transaction Shield, a premium opt-in security upgrade that adds transaction loss protection and 24/7 priority support to its wallet. The service extends MetaMask’s security stack by covering losses up to $10,000 per month for transactions the platform deems safe through automated contract checks and simulations. The subscription costs $9.99 per month or $99 annually, with a 14 day free trial and a $20 discount for annual plans. Coverage is currently available on MetaMask Extension, with mobile support coming later. Transaction Shield applies to approved actions on networks such as Ethereum, Linea, Arbitrum, Avalanche, Optimism, Base, Polygon, BSC, and Sei. Supported interactions include DeFi swaps, lending activity, NFT mints and sales on trusted marketplaces, and verified airdrop claims. The service does not cover compromised wallets, market losses, or protocol exploits. Users must file claims within 21 days, with most reimbursements processed within 15 business days and paid in mUSD at the current market rate. Source: https://cryptobriefing.com/metamask-launches-transaction-shield-for-enhanced-user-security/The post MetaMask rolls out Transaction Shield, a new transaction loss protection feature appeared on BitcoinEthereumNews.com. Key Takeaways MetaMask introduces Transaction Shield, a premium opt in security upgrade with transaction loss protection and priority support. Subscribers receive coverage up to $10,000 per month for transactions deemed safe by MetaMask’s security systems. MetaMask introduced Transaction Shield, a premium opt-in security upgrade that adds transaction loss protection and 24/7 priority support to its wallet. The service extends MetaMask’s security stack by covering losses up to $10,000 per month for transactions the platform deems safe through automated contract checks and simulations. The subscription costs $9.99 per month or $99 annually, with a 14 day free trial and a $20 discount for annual plans. Coverage is currently available on MetaMask Extension, with mobile support coming later. Transaction Shield applies to approved actions on networks such as Ethereum, Linea, Arbitrum, Avalanche, Optimism, Base, Polygon, BSC, and Sei. Supported interactions include DeFi swaps, lending activity, NFT mints and sales on trusted marketplaces, and verified airdrop claims. The service does not cover compromised wallets, market losses, or protocol exploits. Users must file claims within 21 days, with most reimbursements processed within 15 business days and paid in mUSD at the current market rate. Source: https://cryptobriefing.com/metamask-launches-transaction-shield-for-enhanced-user-security/

MetaMask rolls out Transaction Shield, a new transaction loss protection feature

Key Takeaways

  • MetaMask introduces Transaction Shield, a premium opt in security upgrade with transaction loss protection and priority support.
  • Subscribers receive coverage up to $10,000 per month for transactions deemed safe by MetaMask’s security systems.

MetaMask introduced Transaction Shield, a premium opt-in security upgrade that adds transaction loss protection and 24/7 priority support to its wallet.

The service extends MetaMask’s security stack by covering losses up to $10,000 per month for transactions the platform deems safe through automated contract checks and simulations.

The subscription costs $9.99 per month or $99 annually, with a 14 day free trial and a $20 discount for annual plans. Coverage is currently available on MetaMask Extension, with mobile support coming later.

Transaction Shield applies to approved actions on networks such as Ethereum, Linea, Arbitrum, Avalanche, Optimism, Base, Polygon, BSC, and Sei. Supported interactions include DeFi swaps, lending activity, NFT mints and sales on trusted marketplaces, and verified airdrop claims.

The service does not cover compromised wallets, market losses, or protocol exploits. Users must file claims within 21 days, with most reimbursements processed within 15 business days and paid in mUSD at the current market rate.

Source: https://cryptobriefing.com/metamask-launches-transaction-shield-for-enhanced-user-security/

Market Opportunity
OPT Logo
OPT Price(OPT)
$0.002192
$0.002192$0.002192
+0.04%
USD
OPT (OPT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26